Myeloid growth factors in oncology

Bibliography

• GRATWOHL A, HERMANS J, BALDOMERO H: Haemato-poietic precursor cell transplants in Europe: activity in 1994. Report from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Trans-plant. (1996) 17:137–148
   PubMed Web of Science ®Google Scholar
• American Society of Clinical Oncology recommenda-tions for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J. Clin. Oncol (1994) 12:2471–2508.
   PubMed Web of Science ®Google Scholar
• ••Standard guidelines for the present use of growth factors.
   Google Scholar
• CRAWFORD J. OZER H, STOLLER R et al.: Reduction bygranulocyte colony stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer (r-metHuG-CSF). New Engl. J. Med. (1991) 325:164–170.
   Google Scholar
• TRILLET-LENOIR V, GREEN J, MANEGOLD C et al: Recom-binant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemother-apy. Eur. J. Cancer (1993) 29A:319–324.
   PubMed Web of Science ®Google Scholar
• PETTENGELL R, GURNEY H, RADFORD JA et al: Granulo-cyte colony stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a random-ized controlled trial. Blood (1992) 80:1433–1436.
   Web of Science ®Google Scholar
• JONES SE, SCHOTTSTAEDT MW, DUNCAN LA et al: Ran-domised double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate dose fluorouracil, doxorubicin and cyclophospha-mide adjuvant chemotherpay program for Stage II and III breast cancer. J. Clin. Oncol. (1996) 14:2976–2983.
   PubMed Web of Science ®Google Scholar
• MOREAU P, FIERE D, BEZWODA WR et al: Prospectiverandomised placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in pa-tients with multiple myeloma. j Clin. Oncol. (1997) 15:660–666.
   PubMed Web of Science ®Google Scholar
• BOOGAERTS M, CAVALLI F, CORTES-FUNES H et al: Granulocyte growth factors: achieving a consensus. Ann. Oncol. (1995) 6:237–244.
   PubMed Web of Science ®Google Scholar
• ••European guidelines for the use of growth factors.
   Google Scholar
• TO LB, HAYLOCK DN, SIMMONS PJ, JUTTNER CA: The bi- ology and clinical uses of blood stem cells. Blood (1997) 89:2233–2258.
   PubMed Web of Science ®Google Scholar
• •Excellent review of the clinical uses of mobilised progenitor blood cells.
   Google Scholar
• LINK H, BOOGAERTS MA, CARELLS AM eta].: A controlled trial of recombinant human granulocyte colony stimu-lating factor after total body irradiation, high-dose chemotherapy, and autologous bone marrow trans-plantation for lymphoblastic leukaemia or malignant lymphoma. Blood (1992) 80:2188–2195.
   Google Scholar
• LINCH DC, SCARFFE H, PROCTOR S et al.: Randomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony stimulating factor after bone marrow transplantation. Bone Mar-row Transplant. (1993) 11:307–311.
   PubMed Web of Science ®Google Scholar
• DE WITTE T, GRATWOHL A, VAN DER LELY N: Recombi-nant human granulocyte-macrophage colony-stimulating factor acceleraes neutrophil and mono-cyte recovery after allogeneic T-cell depleted bone marrow transplantation. Blood (1992) 79:1359–1365.
   PubMed Web of Science ®Google Scholar
• SCHMITZ N, DREGER P, ZANDER AR et al.: Results of a randomised, controlled, multicentre study of recom-binant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Bone Marrow Transplant. (1995) 15:261–266.
   PubMed Web of Science ®Google Scholar
• •Important randomised evidence for growth factors post-bone marrow transplant.
   Google Scholar
• VOSE JM, BIERMAN PJ, KESSINGER A et al.: The use of re-combinant human granulocyte-macrophage colony-stimulating factor for the treatment of delayed engraft-ment following high dose therapy and autologous hae-matopoietic stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant. (1991) 7:139–143.
   PubMed Web of Science ®Google Scholar
• SCHMITZ N, LINCH DC, DREGER P et al.: Randomised trial of filgrastim-mobilised peripheral blood progeni-tor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet (1996) 347:353–357.
   PubMed Web of Science ®Google Scholar
• ••Early trial showing the advantages of mobilised stem cellsover bone marow transplant.
   Google Scholar
• CHAO NJ, SCHRIBER JR, GRIMES K etal.: Granulocyte col- ony stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet re-covery after high dose chemotherapy. Blood (1993) 81:2031–2035.
   Google Scholar
• •Early trial showing advantages of mobilised stem cells.
   Google Scholar
• SMITH TJ, HILLNER BE, SCHMITZ N et al.: Economic analysis of a randomised clinical trial to compare filgrastim-mobilised peripheral-blood progenitor-cell transplantation and autologous bone marrow trans-plantation in patients with Hodgkin's and non-Hodgkin's lymphoma. J. Clin. Oncol. (1997) 15:5–10.
   PubMed Web of Science ®Google Scholar
• •Important cost analysis of relative transplant procedures.
   Google Scholar
• SIENA S, BREGNI M, BRANDO B et al.: Flow cytometry forclinical estimation of circulating haematopoietic pro-genitors for autologous transplantation in cancer pa-tients. Blood (1991) 77:400–405.
   PubMed Web of Science ®Google Scholar
• STEWART AK, KEATING IA, ANANIA S, NAYAR R, SUTHER-LAND R: Optimising the CD34+ and CD34+ Thy-1+ stem cell content of peripheral blood collections. Exp. He-matol. (1995) 23:1619–1623.
   PubMed Web of Science ®Google Scholar
• SIMMONS PJ, MASINOVSKY B, LONGENECKER BM et al.: Vascular cell adhesion molecule-1 expressed by bone marrow stromal cells mediates the binding of haema-topoietic progenitors. Blood (1992) 80:388–395.
   PubMed Web of Science ®Google Scholar
• TURNER ML: Regulation of haematopoietic progenitor cell migration, mobilization and homing. Stem Cells (1994) 12:227–229.
   PubMed Web of Science ®Google Scholar
• SIMMONS PJ, ZANNETTINO A, GRONTHOS S, LEAVESLEY D: Potential adhesion mechanisms for localization of haematopoietic progenitors to bone marrow stroma. Leuk Lymphoma (1994) 12:353–363.
   PubMed Web of Science ®Google Scholar
• PAPAYANNOPOULOU T, NAKAMOTO B: Peripheralisa-tion of a haematopoietic progenitors in primates treated with anti-VLA-4 integrin. Proc. Nati Acad. Sci. USA (1993) 90:9374–9378.
   PubMed Web of Science ®Google Scholar
• MOHLE R, HAAS R, HUNSTEIN W: Expression of adhe-sion molecules and c-kit on CD34 haematopoietic progenitor cells. Comparison of cytokine mobilized blood stem cells with normal bone marrow and pe-ripheral blood. J. Haematother. (1993) 2:483–489.
   Google Scholar
• TO LB, HAYLOCK DN, DOWSE T et al.: A comparative study of the phenotype and proliferative capacity of peripheral blood (PB) CD34 cells mobilized by four different protocols and those of steady-phase PB and bone marrow CD34+ cells. Blood (1994) 84:2930–2939.
   PubMed Web of Science ®Google Scholar
• •Detailed comparison of different mobilisation regimens.
   Google Scholar
• KOVACH NL, LIN N, YEDNOCK T, HARLAN JM, BROUDYVC: Stem cell factor modulates activity of a4b1 and a5b1 integrins expressed on haematopoietic cell lines. Blood (1995) 85:159–167.
   PubMed Web of Science ®Google Scholar
• LEVESQUE J-P, HAYLOCK DN, SIMMONS PJ: Cytokine regulation of proliferation and cell adhesion are corre-lated events in human CD34+ haematopoietic progeni-tors. Blood (1996) 88:1168–1176.
   PubMed Web of Science ®Google Scholar
• TO LB, SHEPPARD KM, HAYLOCK DN et al.: Single highdose of cyclophosphamide enables the collection of high numbers of haematopoietic stem cells from the peripheral blood. Exp Hematol (1989) 18:442–447.
   Web of Science ®Google Scholar
• •Basic refereence for most common mobilisation regimen.
   Google Scholar
• SIMMONS PJ, LEAVESLEY DI, LEVESQUE J-P et al.: The mo- bilization of primitive haemopoietic progenitors into the peripheral blood. Polyfunctionality of haemopoie-tic regulators. Stem Cells (1994) 12 (Suppl. 0:187–201.
   Google Scholar
• •Current reference for mobilisation of peripheral blood stem cells.
   Google Scholar
• BARRETT AJ, LONGHURST P, SNEATH P, WATSON JG: Mo- bilization of CFU-C by exercise and ACTH induced stress in man. Exp. Hematol. (1978) 6:590–594.
   PubMed Web of Science ®Google Scholar
• KORBLING M, FLIEDNER TM, PFFIEGER H. Collection oflarge quantities of granulocyte macrophage progeni-tor cells (CFUs) in man by means of continuous flow leukophoresis. Scan. J. Haematol. (1980) 24:22–28.
   Google Scholar
• TO LB, DYSON PG, BRANFORD AL et al: Peripheralblood stem cells collected in very early remission pro-duce rapid and sustained autologous haematopoietic reconstitution in acute non lymphoblastic leukaemia. Bone Marrow Transplant (1987) 2:103–108.
   PubMed Web of Science ®Google Scholar
• REIFFERS J, BERNARD P, DAVID B et al.: Successfulautologous transplantation with peripheral blood haematopoietic cells in a patients with acute leukae-mia. Exp. Hematol. (1986) 14:312–315.
   PubMed Web of Science ®Google Scholar
• ROWLINGS PA, RAWLING CA, TO LB, BAYLY JL, JUTTNERCA: A comparison of peripheral blood stem cell mobi-lization after chemotherapy with cyclophosphamide as a single agent in doses of 4g/m2 in patients with ad-vanced cancer. Aust NZ J Med (1992) 22:660–664.
   PubMedGoogle Scholar
• •Important reference for mobilisation of peripheral blood stem cells.
   Google Scholar
• SCHVVARTZBERG LS, BIRCH R, HAZELTON B et al.: Pe- ripheral blood stem cell mobilization by chemother-apy with and without recombinant human granulocyte colony-stimulating factor. J. Hematother. (1992) 1:317–327.
   PubMedGoogle Scholar
• •Basic text for chemotherapy-induced mobilisation.
   Google Scholar
• KNUDSEN LM, GAARSDAL E, JENSEN L et al.: Improvedpriming for mobilisation of and optimal timing for harvest of peripheral blood stem cells. J. Hematother. (1996) 5:399–406.
   PubMedGoogle Scholar
• BENSINGER W, APPELBAUM F, ROWLEY S et al.: Factorsthat influence collection and engraftment of autolo-gous peripheral blood stem cells. J Clin Oncol (1995) 13:2547–2555.
   PubMed Web of Science ®Google Scholar
• •Basic text on mobilisation.
   Google Scholar
• GIANNI AM, BREGNI M, SIENA S et al.: Recombinant hu- man granulocyte-macrophage colony-stimulating fac-tor reduces hematologic toxicity and widens clinical applicability of high dose cyclophosphamide treat-ment in breast cancer and non-Hodgkin's lymphoma. Clin. Oncol (1990) 8:768–778.
   Web of Science ®Google Scholar
• •Important early paper on the use of growth factors.
   Google Scholar
• SHERIDAN WP, BEGLEY CG, JUTTNER CA et al.: Effect ofperipheral blood progenitor cells mobilized by filgras-tim (G-CSF) on platelet recovery after high dose che-motherapy. Lancet (1992) 339:640–644.
   PubMed Web of Science ®Google Scholar
• DEMUYNCK H, PETTENGELL R, DE CAMPOS E, DEXTERTM, TESTA NG: The capacity of peripheral blood stem cells mobilised with chemotherapy plus G-CSF to re-populate irradiated marrow stroma in vitro is similar to that of bone marrow. Eur. J. Cancer (1992) 28:381–386.
   PubMed Web of Science ®Google Scholar
• SHERIDAN WP, BEGLEY CG, TO LB et al: Phase II studyof autologous filgrastim (G-CSF) -mobilised peripheral blood progenitor cells to restore hematopoiesis after high-dose chemotherapy for lymphoid malignancies. Bone Marrow Transplant (1994) 14:105–111.
   PubMed Web of Science ®Google Scholar
• BENDER JG, TO LB, WILLIAMS S, SCHWARTZBERG LS: De-fining a therapeutic dose of peripheral blood stem cells. J. Hematother. (1992) 1:329–335.
   PubMedGoogle Scholar
• BENTLEY SA, BRECHER ME, POWELL E, SERODY JS, WILEY JM, SHEA TC. Long-term engraftment failure af-ter marrow ablation and autologous haematopoietic reconstitution: differences between peripheral blood stem cell and bone marrow recipients. Bone Marrow Transplant (1997) 19:557–563.
   PubMed Web of Science ®Google Scholar
• •Further text showing advantage of peripheral blood stem cell transplants.
   Google Scholar
• DREGER P, KLOSS M, PETERSEN B et al: Autologous pro- genitor cell transplantation: prior exposure to stem-cell toxic drugs determines yield and engraftment of peripheral blood progenitor cells but not of bone mar-row grafts. Blood (1995) 86:3970–3978.
   PubMed Web of Science ®Google Scholar
• •Excellent description of factors asociated with poor mobili-sation and engraftment.
   Google Scholar
• PAPADOPOULOS KP, AYELLO J, TUGULES S et al.: Har- vest quality and factors affecting collection and en-graftment of CD34+ cells in pateints with breast cancer scheduled for high-dose chemotherapy and peripheal blood progenitor cell support. J Hematother (1997) 6:61–68.
   PubMedGoogle Scholar
• •Further paper on factor determining progenitor cell harvest.
   Google Scholar
• SINGHAL S, POWLES R, TRELEAVEN J, HORTON C, MEHTA J: Long-term safety of GM-CSF (molgramostim) ad-ministration after allogeneic bone marrow transplan-tation for hematologic malignancies: five-year follow-up of a double-blind randomised placebo-controlled study. Leukaemia and Lymphoma (1997) 24:301–307.
   PubMed Web of Science ®Google Scholar
• •Recent paper showing no long-term toxicity with GM-CSF.
   Google Scholar
• AGLIETTA M, PIACIBELLO W, SANAVIO F et al.: Kineticsof human haematopoietic cells after in vivo admini-stration of granulocyte-macrophage colony-stimulating factor. J. Clin. Invest. (1995) 83:551–554.
   Web of Science ®Google Scholar
• HAAS R, HO AD, BREDTHAUER U et al.: Successfulautologous transplantation of blood stem cells mobi-lised with recombinant human granulocyte-macrophage colony-stimulating factors. Exp. Hematol (1990) 18:94–99.
   PubMed Web of Science ®Google Scholar
• RAGNHAMMER P: Antitumoral effect of GM-CSF with orwithout cytokines and monoclonal antibodies in solid tumours. Medical Oncol. (1996) 13:167–176.
   PubMed Web of Science ®Google Scholar
• FAGERBERG J: Granulocyte macrophage colony stimu-lating factor as an adjuvant in tumour mmunotherapy. Medical Oncol.(1996) 13:155–160.
   PubMed Web of Science ®Google Scholar
• SI Z, HERSEY P, COATES AS: Clinical responses and lym-phoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Melanoma Re-search (1996) 6:247–255.
   PubMed Web of Science ®Google Scholar
• KISHITA M, MOTOJIMA H, OH-EDA M et al.: Stability ofgranulocyte colony stimulating factor (G-CSF) in se-rum. Clin. Res (1992) 26:221–224.
   Google Scholar
• WELLS M: Influence of glycosylation on the activity ofrG-CSFs in vivo studies. Activity in animal models: biological potency of different rG-CSFs in CD rats. Int. Haem. (1996) 64\(Suppl. 1):27–28.
   Google Scholar
• LINCH D: Activity in clinical setting: Comparison ofPBPC mobilization with different rG-CSFs in patients with lymphoma. Int. J. Haem. (1996) 64\(Suppl. 2):29.
   Google Scholar
• ORTUNO-GINER F, DE ARRIBA F: Comparison of PBPCmobilization with different rG-CSFs in cancer patients. Int. J. Haem. (1996) 64\(Suppl. 2):31–32.
   Google Scholar
• •Paper showing equivalent efficacy of growth factors.
   Google Scholar
• HOLUND M, BENGESSON M, COUR-CHABERNAUD Y et al. Glycosylated rHuG-CSF is more potent than non-glycosylated rHuG-CSF in mobilisation of peripheral blood progenitor cells (PBPC) in healthy volunteers. Blood (1995) 86(Suppl 1):465A.
   Google Scholar
• BEYER J, SCHVVELLA N, ZIGSEN J et al.: Haematopoietic rescue after high-dose chemotherapy using autolo-gous peripheral-blood progenitor cells or bone mar-row: A randomized comparison. J. Clin. Oncol. (1995) 13:1328–1334.
   PubMed Web of Science ®Google Scholar
• •Randomised trial of peripheral blood or bone marrow stem cells.
   Google Scholar
• BROXMEYER HE, BENNINGER L, PATEL SR, BENJAMIN RS, VADHAN-RAJ S: Kinetic response of human marrow myeloid progenitor cells to in vivo treatment of pa-tients with granulocyte colony-stimulating factor is different from the response to treatment with granulocyte-macrophage colony-stimulating factor. Exp. Hematol (1994) 22:100–107.
   PubMed Web of Science ®Google Scholar
• •Randomised study of G-CSF compared to GM-CSF.
   Google Scholar
• JANSSEN WE, SMILEE RC, ELFENBEIN GJ: A prospective randomised trial comparing blood- and marrow-derived stem cells for haematopoietic replacement fol-lowing high-dose chemotherapy. J. Hematother. (1995) 4:139–145.
   PubMedGoogle Scholar
• ••Randomised trial of peripheral blood or bone marrow stemcells.
   Google Scholar
• DAMIANI D, FANIN R, SILVESTRI F eta]. Randomised trial of autologous filgrastim-primed bone marrow trans-plantation versus filgrastim-mobilised peripheral blood stem cell transplantation in lymphoma patients. Blood (1997) 90:36–42.
   Google Scholar
• ••Seminal paper comparing bone marrow to peripheral bloodstem cells.
   Google Scholar
• HOLDEN SA, TEICHER BA, AYASH LJ, FREI E: A preclini-cal model for sequential high-dose chemotherapy. Cancer Chemother. Pharmacol (1995) 36:61–64.
   PubMed Web of Science ®Google Scholar
• GIANNI AM, SIENA S, BREGNI M et al.: Efficacy toxicityand applicability of high-dose sequential chemother-apy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five year re-sults. J. Clin. Oncol. (1997) 15:2312–2321.
   PubMed Web of Science ®Google Scholar
• •Introduction to high dose sequential chemotherapy.
   Google Scholar
• DREGER P, VON NEUHOFF N, KUSE R et al.: Sequential high dose therapy and autologous stem cell transplan-tation for treatment of mantle cell lymphoma. Ann. Oncol. (1997) 8:401–403.
   PubMed Web of Science ®Google Scholar
• •Further introduction to high dose sequential chemotherapy.
   Google Scholar
• GIANNI AM, TARELLA C, BREGNI M et al.: High-dose se- quential chemoradiotherapy, a widely applicable regi-men, confers survival benefit to patients with high-risk multiple myeloma. J. Clin. Oncol. (1994) 12:503–509.
   PubMed Web of Science ®Google Scholar
• •High dose sequential chemotherapy with growth factor support.
   Google Scholar
• KERN W, SCHLEYER E, UNTERHALT M, WORMANN B, BUCHNER T, HIDDEMANN W: High antileukemic activ-ity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leuke-mias. Results of a clinical Phase II study. Cancer (1997) 79:59–68.
   Google Scholar
• •Improved efficacy from high dose chemotherapy supported by growth factors.
   Google Scholar
• LAVER J, AMYLON M, DESAI S et al.: Randomized trial of r-metHu granulocyte colony-stimulating factor in an intensive treatment for T-cell leukaemia and advanced-stage lymphoblastic lymphoma of child-hood: a Pediatric Oncology Group pilot study. J. Clin. Oncol. (1998) 16:522–526.
   PubMed Web of Science ®Google Scholar
• •Application of high dose chemotherapy to paediatric lymphomas.
   Google Scholar
• JAKACKI RI, JAMISON C, HEIFETZ SA et al.: Feasibility ofsequential high-dose chemotherapy and peripheral blood stem cell support for pediatric central nervous system malignancies. Med. Paed. Oncol. (1997) 29:553–559.
   PubMedGoogle Scholar
• HAAS R, SCHMID H, HAHN U et al. Tandem high-dosetherapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective ad-junct tretment for high-risk primary breast cancer. Eur. J. Cancer (1997) 33:372–378.
   PubMed Web of Science ®Google Scholar
• •Improved efficacy of high dose sequential chemotherapy.
   Google Scholar
• PEREY L, ROSTI G, LANGE A et al. Sequential high-dose ICE chemotherapy with circulating progenitor cells (CPC) in small cell lung cancer: an EBMT study. Bone Marrow Transplant (1996) 18(Suppl 1):40–43.
   PubMed Web of Science ®Google Scholar
• •Further example of high dose sequential chemotherapy.
   Google Scholar
• GRENMAN SE, RANTANEN VT, SALMI TA. High-dose che-motherapy with autologous stem cell support in ad-vanced ovarian cancer. Annals of Medicine (1996) 28:151–158.
   Google Scholar
• BENSINGER W, WEAVER FR, APPELBAUM FR et al. Trans-plantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood (1995) 85:1655–1658.
   PubMed Web of Science ®Google Scholar
• SCHMITZ N, DREGER P, SUTTORP M et al.: Primary trans-plantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony stimulating factor). Blood (1995) 85:1666–1672.
   PubMed Web of Science ®Google Scholar
• •Early experience with allogeneic mobilisation of peripheral blood progenitor cells.
   Google Scholar
• SICA S, RUTELLA S, DI MARIO A et al. rhG-CSF in healthy donors: mobilisation of peripheral haematopoietic progenitors and effect on peripheral blood leuko-cytes. J Hematol (1996) 5:391–397.
   Google Scholar
• •Safety of allogeneic harvesting from healthy donors.
   Google Scholar
• BASSER RL, TO LB, BEGLEY CG et al: Adjuvant treatment of women with high risk breast cancer using multiple cycles of high dose chemotherapy supported by Fil-grastim (G-CSF) mobilised peripheral blood progeni-tor cells. Clin. Cancer Res. (1995) 1:715.
   PubMed Web of Science ®Google Scholar
• WALLER CF, BERTZ H, WENGER MK et al.: Mobilization of peripheral blood progenitor cells for allogeneic trans-plantation: Efficacy and toxicity of a high-dose rhG-CSF regmen. Bone Marrow Transplant (1996) 18:279–283.
   PubMed Web of Science ®Google Scholar
• •Use of G-CSF for mobilisation of peripheral blood progeni-tor cells from allogeneic donors.
   Google Scholar
• ANDERLINI P, KORBLING M, DALE D et al.: Allogeneic blood stem cell transplantation: considerations for do-nors. Blood (1997) 90:903–908.
   PubMed Web of Science ®Google Scholar
• ••Ethical considerations in allogeneic stem celltransplantation.
   Google Scholar
• SCHMITZ N, BACIGALUPO A, LABOPIN M et al.: Trans- plantation of peripheral blood progenitor cells from HLA-identical sibling donors. European Group for Bone Marrow Transplantation (EBM1). Br. J. Haematol. (1996) 95:715–723.
   Google Scholar
• ••European experience of allogeneic stem cell tranplantation.
   Google Scholar
• GLASS B, UHAREK L, ZEIS M et al.: Allogeneic peripheral blood progenitor cell transplantation in a murine model: evidence for an improved graft-versus leukae-mia effect. Blood (1997) 90:1694–1700.
   PubMed Web of Science ®Google Scholar
• SPITZER TR. Allogeneic peripheral blood stem cell transplantation. J. Infusional Chemother. (1996) 6:33–38.
   PubMedGoogle Scholar
• KUSNIERZ-GLAZ CR, STILL BJ, AMANO M et al.: Granulo-cyte colony-stimulating factor-induced comobiliza-tion of CD34-CD8- T cells and hematopoietic progenitor cells (CD34-) in the blood of normal do-nors. Blood (1997) 89:2586–2595.
   PubMed Web of Science ®Google Scholar
• ••Identification of different stem cell subtypes with G-CSF mo-bilised stem cells from healthy donors.
   Google Scholar
• EMERSON G: Ex vivo expansion of haematopoietic pre- cursor, progenitors, and stem cells: the next genera-tion of cellular therapeutics. Blood (1996) 87:3082–3087.
   PubMed Web of Science ®Google Scholar
• •Introduction to the use of ex vivo expansion of stem cells.
   Google Scholar
• SCHIMAZAKI C, OKU N, UCHIYAMA H et al.: Effect of granulocyte colony-stimulating factor on haemato-poietic recovery after peripheral blood progenitor cell transplantation. Bone Marrow Transplant. (1994) 13:271–278.
   PubMed Web of Science ®Google Scholar
• CHANG J, MORGENSTERN G, DEAKIN D et al.: Reconsti-tution of haematopoietic system with autologous mar-row taken during relapse of acute myeloblastic leukaemia and grown in long-term culture. Lancet (1986) i:294–296.
   Google Scholar
• HAYLOCK DN, TO LB, DOWSE TL, JUTTNER CA, SIMMONS PJ: Ex vivo expansion and maturation of peripheral blood CD34+ cells into the myeloid lineage. Blood (1992) 89:1405–1414.
   Google Scholar
• BRUGGER W, HEIMFELD S, BERENSON RJ, MERTELS-MANN R, KANZ L: Reconstitution of hematopoiesis af-ter high-dose chemotherapy by autologous progenitor cells generated ex-vivo. New Engl. J. Med. (1995) 333:283–285.
   PubMed Web of Science ®Google Scholar
• BROXMEYER HE, DOUGLAS GW, HANGOC G et al.: Hu-man umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc. Natl. Acad. Sci. USA (1989) 86:3828–3833.
   PubMed Web of Science ®Google Scholar
• •Description of an important source of allogeneic stem cells.
   Google Scholar
• DE BRUYN C, DELFORGE A, BRON D et al.: Ex vivo ex- pansion of CD34+ CD38- cord blood cells. J. Hematol (1997) 6:93–102.
   Google Scholar
• •Introduction to the concept of ex vivo customised stem cell expansion.
   Google Scholar
• GEHLING UM, RYDER JW, HOGAN CJ et al.: Ex vivo ex- pansion of megakaryocyte progenitors: effect of vari-ous growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF- mobilised periph-eral blood. Exp. Hematol. (1997) 25:1125–1139.
   PubMed Web of Science ®Google Scholar
• •Conditions to produce megakaryocyte precursors in ex vivo culture.
   Google Scholar
• MAKINO S, HAYLOCK DN, DOWSE T et al.: Ex vivo cul- ture of peripheral blood CD34+ cells: effects of hemato-poietic growth factors on production of neutrophilic precursors. J. Hematol. (1997) 6:475–489.
   Google Scholar
• •Conditions to produce neutrophil progenitors in ex vivo culture.
   Google Scholar
• PIACIBELLO W, SANAVIO F, GARETTO L et al.: Extensive amplification and self-renewal of human primitive he-matopoietic stem cells from cord blood. Blood (1997) 89:2644–2653.
   PubMed Web of Science ®Google Scholar
• •Condition for culture of cord blood.
   Google Scholar
• BHATIA R, MCGLAVE PB, MILLER JS et al.: A clinically suitable ex vivo expansion culture system for LTC-IC and CFC using stroma-conditioned medium. Exp. He-matol. (1997) 25:980–991.
   PubMed Web of Science ®Google Scholar
• •Identification of early stem cells from ex vivo culture.
   Google Scholar
• BRIDDELL RA, KERN BP, ZILM KL, STONEY GB, MCNIECEIK: Purification of CD34+ cells is essential for optimal ex vivo expansion of umbilical cord blood cells. J. He-matol. (1997) 6:145–150.
   Google Scholar
• KELLER MR, EMERSON SG, PALSSON BO: Large-scale ex-pansion of human stem and progenitor cells from bone marrow mononuclear cells in continuous perfu-sion cultures. Blood (1993) 82:378–384.
   PubMed Web of Science ®Google Scholar
• TRAYCOFF CM, KOSAK ST, GRIGSBY S, SROUR EF: Evaluation of ex vivo expansion potential of cord blood and bone marrow haemopoietic progenitor cells using cell tracking and limiting dilution analysis. Blood (1995) 85:2059–2068.
   PubMed Web of Science ®Google Scholar
• VERFAILLIE CM: Soluble factor (s) produced by humanbone marrow stroma increase cytokine-induced pro-liferation and maturation of primitive haemopoietic progenitors while preventing their terminal differen-tiation. Blood (1993) 82:2045–2053.
   PubMed Web of Science ®Google Scholar
• BARNETT MJ, EAVES CJ, PHILLIPS GL et al.: Autograftingwith cultured marrow in chronic myeloid leukaemia. Results of a pilot study. Blood (1994) 84:724–732.
   PubMed Web of Science ®Google Scholar
• KOLLER MR, MANCHEI I, PALSSON BO: Importance of parenchymal: stromal cells ratio for the ex vivo recon-struction of human haemopoiesis. Stem Cells (1997) 15:305–313.
   PubMed Web of Science ®Google Scholar
• •Introduction to stroma in the ex vivo expansion of progenitors.
   Google Scholar
• KOLLER MR, MANCHEI I, BROFF DA, PALSSON BO: Donorto donor variability in the expansion potential of hu-man bone marrow cells is reducing by accessory cells but not by soluble growth factors. Exp. Haematol. (1996) 24:1484–1493.
   PubMed Web of Science ®Google Scholar
• SUNDMAN-ENGBERG B, TIDEFELT U, PAUL C. Effect ofcytokines on the toxicity of cytostatic drugs on leukae-mic cells in vitro and in vivo. Eur. J. Haematol. (1996) 56:1–6.
   PubMed Web of Science ®Google Scholar
• GORE SD, WENG LJ, BURKE PJ: Biologic and clinical im-pact of growth factor (GF) augmentation of post-remission chemotherapy for myeloid leukaemia. Blood (1994) 84:582A.
   PubMed Web of Science ®Google Scholar
• BUCHNER T, HIDDLEMANN W, WORMANN R et al.: GM-CSF multiple course priming and long-term admini-stration in newly diagnosed AML. Hematologic and therapeutic effects. Blood (1994) 84:27A.
   Google Scholar
• HEIL G, HOELZER D, SANZ MA et al.: A randomised, double-blind, placebo-controlled, Phase III study of fil-grastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukae-mia. The International Acute Myeloid Leukaemia Study Group. Blood (1997) 90:4710–4718.
   Google Scholar
• •Class I evidence for use of G-CSF in myeloid leukaemia.
   Google Scholar
• DOMBRET H, CHASTANG C, FENAUX P et al.: A con-trolled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukaemia AML Co-operative Study Group. New Engl. J. Med. (1995) 332:1678–1683.
   PubMed Web of Science ®Google Scholar
• •Class I evidence for use of G-CSF in myelogenous leukaemia.
   Google Scholar
• ROWE JM, ANDERSEN JW, MAZZA JJ et al.: A randomised placebo controlled Phase ill study of granulocyte-macrophage colony-stimulating factor in adult pa-tients (>55 to 70 years of age) with acute myelogenous leukaemia. A study of the Eastern Cooperative Oncol-ogy Group (E1490). Blood (1995) 86:457–462.
   Google Scholar
• •Class I evidence for use of G-CSF in myelogenous leukaemia.
   Google Scholar
• STONE RM, BERG DT, GEORGE SL et al.: Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukaemia. New Engl. J. Med. (1995) 332:1671–1677.
   PubMed Web of Science ®Google Scholar
• ZITTOUN R, SUCIU S, MANDELLI F et al.: Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukaemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukaemia Coop-erative Group. J. Clin. Oncol (1996) 14:2150–2159.
   PubMed Web of Science ®Google Scholar
• ••Class I evidence for use of G-CSF in myelogenousleukaemia.
   Google Scholar
• GELLER RB. Use of cytokines in the treatment of acute myelocytic leukaemia: a critical review. J. Clin. Oncol (1996) 14:1371–1382.
   PubMed Web of Science ®Google Scholar
• ••Excellent overview of growth factors in AML.
   Google Scholar
• BRUGGER W, BROSS K, FRISCH J et al.: Mobilization of peripheral blood progenitor cells by sequential ad-ministration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following poly-chemotherapy with etoposide, ifosfamide and cis-platin. Blood (1992) 70:1193–1200.
   Google Scholar
• TO LB, RAWLING C, ANDARY C et al.: The efficacy of se-quential/combined IL-3/GM-CSF administration in pe-ripheral blood (PB) progenitor mobilization. Blood (1993) 82(Suppl 1):319A.
   Google Scholar
• •Early evidence for the combination of IL-3 with GM-CSF.
   Google Scholar
• LEMOLI RM, ROSTI G, VISANI G et al.: Concomitant and sequential administration of recombinant human interleukin-3 to accelerate hematopoietic recovery af-ter autologous bone marrow transplantation for ma-lignant lymphoma. J. Clin. Oncol (1996) 14:3018–3025.
   PubMed Web of Science ®Google Scholar
• ••Background evidence for the use of IL-3 with GM-CSF.
   Google Scholar
• GEISSLER K, VALENT P, MAYER P et al.: Recombinant hu-man interleukin-3 expands the pool or circulating he-matopoietic progenitor cells in primates and synergism with recombinant granulocyte/macro-phage colony-stimulating factor. Blood (1990) 75:2305–2310.
   PubMed Web of Science ®Google Scholar
• •Early use of PIXY321.
   Google Scholar
• LAPIDOT T, PFLUMIO F, DOEDENS M et al.: Cytokine stimulation of multilineage hematopoiesis from im-mature human cells engrafted in SCID mice. Science (1992) 255:1137–1141.
   PubMed Web of Science ®Google Scholar
• CAIRO MS, LAW P, VAN DE VEN C et al: The in vitro ef-fects of stem cell factor and PIXY321 on myeloid pro-genitor formation (CFU-GM) from immunomagnetic separated CD34+ cord blood. Pediatr. Res. (1992) 32:277–281.
   PubMed Web of Science ®Google Scholar
• MCALISTER IB, TEEPE M, GILLIS S, WILLIAMS DE: Ex vivo expansion of peripheral blood progenitor cells with recombinant cytokines. Exp Hematol. (1992) 20:626–628.
   PubMed Web of Science ®Google Scholar
• PETRUCCI MT, DE FELICE L, RICCIARDI MR et al.: Stem cell factor and PIXY321 in ALL: in vitro study on prolif-erative effects and apoptosis. Cytokines Mol. Ther. (1996) 2:225–230.
   PubMedGoogle Scholar
• NANTEL SH, BERNSTEIN SH, STEVENS DA et al.: Dose es-calation study of PIXY321 post autologous bone mar-row transplant (BMT) for Hodgkin's disease (HD) or non-Hodgkin's disease (NHL). Blood (1995) 86(Suppl 1):871A.
   Google Scholar
• •Early clinical trials of PIXY321.
   Google Scholar
• GHIELMINI M, PETTENGELL R, CONTINHO LH, TESTA N, CROWTHER D: The effect of the GM-CSF/IL-3 fusion protein PIXY321 on the bone marrow and circulating haematopoietic cells of previously untreated patients with cancer. Br. J. Haematol (1996) 93:6–12.
   PubMed Web of Science ®Google Scholar
• •Early clinical trial of PIXY321.
   Google Scholar
• ABBOUD CN, REYKDAL S, LIES VELD JL et al. Prospective randomised trial (NCl/92-0010) comparing the © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(11) efficacy of hematopoietic growth factors for mobilizing pe-ripheral blood stem cells (PBSC) in autologous bone mar-row transplantation: II progenitor mobilization kinetics. Blood (1995) 86 (Suppl. 1):463A.
   Google Scholar
• ••Class I evidence for mobilisation protocols.
   Google Scholar
• WINTER JN, LAZARUS HM, RADEMAKER AF et al.: Com-parison of PIXY321 and GM-CSF for mobilization of pe-ripheral blood progenitor cells (PBPC) in advanced breast cancer. Blood (1995) 86\(Suppl. 1):578A.
   Google Scholar
• •Efficacy of PIXY321 versus GM-CSF - preliminary compara-tive data.
   Google Scholar
• VOSE JM, PANDITE AN, BEVERIDGE RA et al.: Granulocyte-macrophage colony-stimulating fac-tor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autolo-gous bone marrow transplantation for non-Hodgkin's lymphoma: results of a randomised double-blind trial. j Gun. Oncol (1997) 15:1617–1623.
   Web of Science ®Google Scholar
• •Class I evidence for PIXY321 in NHL.
   Google Scholar
• Immunex Corp.: US174608A (1997).
   Google Scholar
• GLASPY J: Clinical applications of stem cell factor. Curr. Opin. Haematol. (1996) 3:223–229.
   PubMedGoogle Scholar
• KOJIMA S, MATSUYAMA T, KODERA Y: Plasma levels and production of soluble stem cell factor by marrow stro-mal cells in patieents with aplastic anaemia. Br. J. Hae-matol. (1997) 99:440–446.
   PubMed Web of Science ®Google Scholar
• BEGLEY CG, BASSER R, MANSFIELD R et al.: Enhanced levels and enhanced clonogenic capacity of blood pro-genitor cells following administration of stem cell fac-tor plus granulocyte colony-stimulating factor to humans. Blood (1997) 90:3378–3389.
   PubMed Web of Science ®Google Scholar
• GLASPY JA, SHPALL EJ, LEMAISTRE CF et al.: Peripheral blood progenitor cell mobilisation using stem cell fac-tor in combination with filgrastim in breast cancer pa-tients. Blood (1997) 90:2939–2951.
   PubMed Web of Science ®Google Scholar
• MOSKOWITZ CH, STIFF P, GORDON MS et al.: Recombi-nant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients - results of a Phase I/II trial. Blood (1997) 89:3136–3147.
   PubMed Web of Science ®Google Scholar
• •Preliminary data from clinical trials using combination of growth factors.
   Google Scholar
• WEAVER A, RYDER D, CROWTHER D, DEXTER TM, TESTA NG: Increased numbers of long-term culture-initiating cells in the apheresis product of patients randomised to receive increasingly doses of stem cell factor admin-istered in combination with chemotherapy and a stan-dard dose of granulocyte colony-stimulating factor. Blood (1996) 88:3323–3328.
   PubMed Web of Science ®Google Scholar
• •Evidence for SCF as an early acting growth factor.
   Google Scholar
• DREXTER HG. Expression of FLT-3 receptor and re-sponse to FLT-3 ligand by leukaemic cells. Leukaemia (1996) 10:588–599.
   PubMed Web of Science ®Google Scholar
• RAPPOLD I, ZIEGLER BL, KOHLER I et al. Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT-3/CD135 receptor ty-rosine kinase. Blood (1997) 90:111–125.
   PubMed Web of Science ®Google Scholar
• YONEMURA Y, KU H, LYMAN SD, OGAWA M: In vitro ex-pansion of haematopoietic progenitors and mainte-nance of stem cells: comparison between FLT3/FLK-2 ligand and KIT ligand. Blood (1997) 89: 1915-1921.
   Google Scholar
• •Use of combination growth factors for ex vivo expansion.
   Google Scholar
• KOLLER MR, OXENDER M, BROTT DA, PALSSON BO: Flt-3 ligand is more potent than c-kit ligand for the syner-gistic stimulation of ex vivo hematopoietic cell expan-sion. J. Hematotherapy (1996) 5:339–459.
   PubMedGoogle Scholar
• •Appropriate combination for effective ex vivo expansion of early stem cells.
   Google Scholar
• RUSTEN LS, LYMAN SD, VELBY OP, JACOBSEN SEW: The FLT-3 ligand is a direct and potent stimulator of the growth of primitive and committed human CD34+ bone marrow progenitor cells in vitro. Blood (1996) 871:1317–1325.
   Google Scholar
• •Appropriate combination for effective ex vivo expansion of early stem cells.
   Google Scholar
• BRASHAM-STEIN C, FLOWER DA, BERSTEIN ID. Regula-tion of colony forming cell generation by flt-3 ligand. Br. J. Hematol. (1996) 94:17–22.
   Google Scholar
• PETZER AL, HOGGE DE, LANDSDORP PM, REID DS, EAVES CJ: Self-renewal of primitive human hemato-poietic cells (longterm culture initiating cells) in vitro and their expansion in defined medium. Proc. Nail Acad. ScL USA (1996) 93:1470–1474.
   PubMed Web of Science ®Google Scholar
• MOLINEUX G, McCREA C, YAN XQ, KERZIC P, McNIECE I: Flt-3 ligand synergises with granulocyte colony-stimulating factor to increase neutrophil numbers and to mobilize peripheral blood stem cells with long-term repopulating potential. Blood (1997) 89:3998–4004.
   PubMed Web of Science ®Google Scholar
• •Importance of maintaining long-term repopulating cell lines.
   Google Scholar
• SUDO Y, SHIMAZAKI C, ASHIHARA E: Synergistic effect of Flt-3 ligand on the granulocyte colony-stimulating factor induced mobilisation of hematopoietic stem cells and progenitor cells into blood in mice. Blood (1997) 89:3186–3191.
   PubMed Web of Science ®Google Scholar
• GABBIANELLI M, PELOSI E, MONTESORO E et al.: Multi-level effects of FLT-3 ligand on human hematopoiesis: expansion of putative stem cells and proliferation of granulomonocytic progenitors/monocytic precur-sors. Blood (1995) 86: 1661-1670.
   Google Scholar
• MOORE TA, ZLOTNIK A: Differential effects of Flk-2/Flt-3 ligand and stem cell factor on murine thymic progenitor cells. J. Immunol (1997) 158:4187–4193 .
   PubMed Web of Science ®Google Scholar
• LISOVSKY M, ESTROV Z, ZHANG Y et al.: Flt-3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukaemia cells: regulation of bc1-2 and bax. Blood (1996) 88:3987–3997.
   PubMed Web of Science ®Google Scholar
• •Important consideration of growth factors on abnormal ex-pansion potential.
   Google Scholar
• PETZER AL, EAVES CJ, BARNETT MJ, EAVES AC: Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukaemia. Blood (1997) 90:64–69.
   PubMed Web of Science ®Google Scholar
• WALLACE EL, CHURCHILL WH, SURGENOR DM et al: Col-lection and transfusion of blood and blood compo-nents in the United States. Transfusion (1995) 35:802–812.
   PubMed Web of Science ®Google Scholar
• LANG SH, WEST CM, JONES L eta].: In vitro effects of re-combinant human megakaryocyte growth and devel-opment factor on primary human tumour colony growth. Oncology (1997) 54:141–145.
   Google Scholar
• MATSUMURA I, IKEDA H, KANAKURA Y: The effects of thrombopoietin on the growth of acute myeloblastic leukaemic cells. Leuk. Lymphoma (1996) 23:533–538.
   PubMed Web of Science ®Google Scholar
• RASKO JE, O'FLAHERTY E, BEGLEY CG: Mpl ligand (MGDF) alone and in combination with stem cell factor (SCF) promotes proliferation and survival of human megakaryocyte, erythroid and granulocyte/macrophage progenitors. Stem Cells (1997) 15:33–42.
   PubMed Web of Science ®Google Scholar
• •Important early data on improving thrombopoiesis.
   Google Scholar
• RAMSFJELL V, BORGE OJ, CUI L, JACOBSEN SE: Thrombo-poietin directly and potently stimulates multilineage growth and progenitor cell expansion from primitive (CD34±CD38-) human bone marrow progenitor cells: Distinct and key interactions with the ligands for c-kit and flt-3, and inhibitory effects of TGF-beta and TNF-alpha. J. Immunol. (1997) 158:5169–5177.
   PubMed Web of Science ®Google Scholar
• OHMIZONO Y, SAKABE H, KIMURA T et al.: Thrombo-poietin augments ex vivo expansion of human cord blood-derived hematopoietic progenitors in combina-tion with stem cell factor and flt-3 ligand. Leukaemia (1997) 11:524–530.
   PubMed Web of Science ®Google Scholar
• MOLINEUX G, HARTLEY C, MCELROY P et al: An analysis of the effects of combined treatment with rhGM-CSF and PEG-rHuMGDF in murine bone marrow trans-plant recipients. Stem Cells (1997) 15:43–49.
   PubMed Web of Science ®Google Scholar
• FARESE AM, HUNT P, CRAB LB, MACVITTIE TJ. Combined administration of recombinant human megakaryo-cyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage he-matopoietic reconstitution in non-human primates af-ter radiation induced marrow aplasia. J. Clin. Invest. (1996) 97:2145–2151.
   PubMed Web of Science ®Google Scholar
• BERTOLINI F, BATTAGLIA M, PEDRAZZOLI P eta].: Mega-karyocytic progenitors can be generated ex vivo and safely administered to autologous peripheral blood progenitor cell transplant recipients. Blood (1997) 89:2679–2688.
   Google Scholar
• •Early clinical data on generation of megakaryocyte progeni-tors ex vivo.
   Google Scholar
• RASKO JE, BASSER RL, BOYD J et al: Multilineage mobili-zation of peripheral blood progenitor cells in humans following administration of PEG-rHuMGDF. Br. J. Hae-mato]. (1997) 97:871–880.
   PubMed Web of Science ®Google Scholar
• •Early clinical data on the use of MGDF.
   Google Scholar
• BASSER RL, RASKO JE, CLARKE K et al.: Thrombopoietic effects of pegylared recombinant human megakaryo-cyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet (1996) 348:1279–1281.
   PubMed Web of Science ®Google Scholar
• O'MALLEY CJ, RASKO JE, BASSER RL et al.: Administra-tion of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation. Blood (1996) 88:3288–3298.
   Google Scholar
• •Early clinical data on the use of MGDF.
   Google Scholar
• VADHAN-RAJ S, MURRAY LI BUESO-RAMOS C et al.: Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombo-poietin in patients with cancer. Ann Int Med (1997) 26:6473–681.
   Google Scholar
• •Early clinical data of thrombopoietin in cancer patients.
   Google Scholar
• BASSER RL, RASKO JE, CLARKE K et al.: Randomized blinded, placebo-controlled Phase I trial of pegylated recombinant human megakaryocyte growth and de-velopment factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood (1997) 89:3118–3128.
   PubMed Web of Science ®Google Scholar
• ••Class I data on the use of MGDF in cancer patients.
   Google Scholar
• WEICH NS, WANG A, FITZGERALD M et al: Recombinant human interleukin-11 directly promotes megakaryo-cytopoiesis in vitro. Blood (1997) 90:3892–3902.
   Web of Science ®Google Scholar
• KAVIANI MD, MASON LE, BREE AG et al. Effects of re- combinant human interleukin 11 on the activation and morphology of peripheral blood platelets and megakaryocytes in nonhuman primates. Blood (1996) 88(Suppl 1):26A.
   Google Scholar
• TEPLER I, ELIAS L, SMITH JW et al.: A randomised placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe throm-bocytopaenia due to chemotherapy. Blood (1996) 87:3607–3614.
   PubMed Web of Science ®Google Scholar
• ISAACS C, ROBERT NJ, BAILEY FA et al: Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopaemia in patients with breast cancer re-ceiving dose-intensive cyclophosphamide and doxo-rubicin. j Clin. Oncol. (1997) 15:3368–3377.
   PubMed Web of Science ®Google Scholar
• WINTIN EF, SRINIVASIAH J, KIM BK et al: Effect of recom-binant human interleukin-6 (rhIL-6) and hhIL-3 on haematopoietic regeneration as demonstrated in a non human primate chemotherapy model. Blood (1994) 84:65–73.
   PubMed Web of Science ®Google Scholar
• PETTENGELL R, LUFT T, DE WYNTER E et al. Effects of interleukin-6 on mobilization of primate haematopoietic cells into the circulation. Br. J. Haema-tol. (1995) 89:237–242.
   Google Scholar
• YOUNG RI, FITZSIMMONS CL, SCARFFE JH et al: Phase I study of recombinant IL-6 in advanced cancer patients. Br. J. Cancer (1994) 69\(Suppl. 21):34A.
   Google Scholar
• URASHINA M, TEOH G, CHANHAN D et al.: Interleukin-6 overcomes p21WAF-1 upregulation and G1 growth ar-rest induced by dexamethasone and interferon-y in multiple lyeloma cells. Blood (1997) 90:279–289.
   PubMed Web of Science ®Google Scholar
• LATER VEER L, ZIJLMANS JM, LINDLEY IJ et al.: Improved survival of lethally irradiated recipient mice transplanted with circulating progenitor cells mobi-lised by I1-8 after pretreatment with stem cell factor. Exp. Hematol. (1996) 24:1387–1393.
   PubMed Web of Science ®Google Scholar
• SONODA Y, KIMURA T, OHMIZONO Y eta].: Action of hu-man interleukin-4 and stem cell factor on erythroid and mixed colony formation by peripheral blood-derived CD34+c-kit(high) or CD34+c-kit(low) cells. Br. Haematol. (1997) 96:781–789.
   Google Scholar